



10/028,156.

C of C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee: Medlyte, Inc, SDSU Heart Institute

Examiner: Louise N. Leavy

Patent No.: 6,881,546

Group Art Unit: 1654

Issue Date: April 19, 2005

Docket No: LPT-3001-UT2

Title: Compositions and Methods for the Treatment and Prevention of Cardiovascular Diseases
and for Identifying Agents therapeutic Therefor.

Attention Certificate of Correction Branch

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Certificate

MAR 14 2006

of Correction

We are transmitting herewith the attached:

- ☒ Request for Certificate of Correction.
- ☒ Certificate of Correction Form – PTO/SB/44 (in duplicate)
- ☒ A return postcard.

Please direct any inquiries to the undersigned attorney at 858 350-9690.

If there are any fees due, please contact the undersigned attorney at 858-350-9690.

Date : March 7, 2006

By: Daniel M. Chambers

BioTechnology Law Group

Daniel M. Chambers

658 Marsolan Ave.

Reg. No: 34,561

Solana Beach, CA 92075

Telephone: (858) 350 9690

Facsimile: (858) 350-9691

Email: dan@biotechnologylawgroup.com

CERTIFICATE OF MAILING PURSUANT TO 37 CFR § 1.8:

The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Attention Certificate of Correction Branch, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Daniel M. Chambers
(Printed Name)

March 7, 2006
(Date of Deposit)

Daniel M. Chambers

Signature



IN UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 6,881,546 Docket No: LPT-3001-UT2
Issue Date: April 19, 2005 Patentee: Medlyte, Inc, SDSU Heart Institute
Title Compositions and Methods for the Treatment and Prevention of Cardiovascular Diseases and for Identifying Agents therapeutic Therefor.

REQUEST FOR CERTIFICATION OF CORRECTION

Attention Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir,

It is requested that a Certificate of Correction be issued correcting printing errors appearing in the above-identified United States patent. Two copies of the text of the Certificate in the suggested form are enclosed.

Issuance of the Certificate of Correction would neither expand nor contract the scope of the claims as properly allowed, and re-examination is not required.

As the error is that of the Patent Office, it is believed that no fee is due. If there are any fees due please contact me at 858-350-9690.

Please direct any inquiries to me at 858 350-9690.

Respectfully Submitted

Date : March 7, 2006
BioTechnology Law Group
658 Marsolan Ave.
Solana Beach, CA 92075
Telephone: (858) 350 9690
Facsimile: (858) 350-9691
Email: dan@biotechnologylawgroup.com

By: Daniel M. Chambers
Daniel M. Chambers
Reg. No: 34,561

CERTIFICATE OF MAILING PURSUANT TO 37 CFR § 1.8:

The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Attention Certificate of Correction Branch, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Daniel M. Chambers
(Printed Name)

March 7, 2006
(Date of Deposit)

Daniel M. Chambers
Signature

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 6,881,546
APPLICATION NO.: 10/028,156
ISSUE DATE : April 19, 2005
INVENTOR(S) : SABBADINI, Roger A.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims:

Column 99, Claim 8, after "receptor is selecte", insert --d--.

Column 99, Claim 8, after "AXOR29" delete "G1", and insert --NRG1--. Claim 8 should read as follows:

8. The method of claim 7 wherein said receptor is selected from the group consisting of Edg-1, Edg-3, Edg-5, Edg-6, Edg-8, the Mil receptor, AXOR29, NRG1, SCaMPER and homologs and isoforms thereof.

Column 100, Claim 13, after "amount", insert --of--. Claim should read as follows:

13. A method for treating or preventing cardiovascular or cerebrovascular disease in a patient, comprising administering to said patient an effective amount of an agent that binds a receptor of a sphingolipid or a sphingolipid metabolite.

Column 100, Claim 20, after "nucleic" delete "avid", insert --acid--. Claim should read as follows:

20. The method of claim 19, wherein said SCaMPER is encoded by a nucleic acid selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

PATENT NO.: 6,881,546

BioTechnology Law Group
658 Marsolan Ave.
Solana Beach, CA 92075-193

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 6,881,546
APPLICATION NO.: 10/028,156
ISSUE DATE : April 19, 2005
INVENTOR(S) : SABBADINI, Roger A.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims:

Column 99, Claim 8, after "receptor is selecte", insert --d--.

Column 99, Claim 8, after "AXOR29" delete "G1", and insert --NRG1--. Claim 8 should read as follows:

8. The method of claim 7 wherein said receptor is selected from the group consisting of Edg-1, Edg-3, Edg-5, Edg-6, Edg-8, the Mil receptor, AXOR29, NRG1, SCaMPER and homologs and isoforms thereof.

Column 100, Claim 13, after "amount", insert --of--. Claim should read as follows:

13. A method for treating or preventing cardiovascular or cerebrovascular disease in a patient, comprising administering to said patient an effective amount of an agent that binds a receptor of a sphingolipid or a sphingolipid metabolite.

Column 100, Claim 20, after "nucleic" delete "avid", insert --acid--. Claim should read as follows:

20. The method of claim 19, wherein said SCaMPER is encoded by a nucleic acid selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

PATENT NO.: 6,881,546

BioTechnology Law Group
658 Marsolan Ave.
Solana Beach, CA 92075-193

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.